Chemomab Therapeutics Income Statement (2017-2025) | CMMB

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Operating items
Research & Development (Quarter)	1.16M	1.31M	1.49M	2.38M	2.75M	2.91M	5.42M	5.89M	6.89M	5.02M	3.38M	3.10M	3.15M	2.93M	2.84M	2.41M	2.49M	1.29M	0.96M	1.09M
Share-based Compensation (IS) (Quarter)							0.84M				0.13M
Selling, General & Administrative (Quarter)	0.54M	1.45M	1.40M	2.64M	2.58M	3.34M	2.89M	2.75M	2.16M	3.17M	0.99M	0.75M	0.90M	0.84M	0.87M	0.80M	0.99M	0.97M	0.88M	0.88M
Restructuring Costs (Quarter)
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)	1.70M	2.75M	2.89M	5.02M	5.32M	6.25M	8.32M	8.64M	9.05M	8.20M	4.37M	3.85M	4.05M	3.77M	3.71M	3.21M	3.49M	2.26M	1.84M	1.97M
Operating Income (Quarter)
EBIT (Quarter)		-2.77M	-2.97M	-5.04M	-5.10M	7.21M	7.84M	7.88M	9.05M	8.20M	3.90M	2.99M	4.05M	3.77M	3.71M	-25.18M			1.84M	-16.22M
Non-operating items
Interest & Investment Income (Quarter)
Non Operating Income (Quarter)
Net income details
EBT (Quarter)		-2.77M	-2.97M	-5.04M	-5.10M	6.73M	8.08M	8.26M	8.73M	7.94M	4.14M	3.42M	3.87M	3.63M	3.48M	-24.93M			1.74M	-16.12M
Tax Provisions (Quarter)						-0.54M		0.01M	0.02M	0.03M	-0.06M
Profit After Tax (Quarter)	-1.70M	-2.77M	-2.97M	-5.04M	-5.10M	6.19M	8.08M	-8.27M	8.75M	7.97M	4.08M	-45.02M	3.87M	3.63M	3.48M	2.96M	3.32M	2.06M	1.74M	1.87M
Income from Continuing Operations (Quarter)		-2.77M	-2.97M	-5.04M	-5.10M	7.28M	8.08M	8.25M	8.71M	7.90M	4.19M	3.42M	3.87M	3.63M	3.48M	-24.93M			1.74M	-16.12M
Consolidated Net Income (Quarter)		-2.77M	-2.97M	-5.04M	-5.10M	7.28M	8.08M	8.25M	8.71M	7.90M	4.19M	3.42M	3.87M	3.63M	3.48M	-24.93M			1.74M	-16.12M
Income towards Parent Company (Quarter)		-2.77M	-2.97M	-5.04M	-5.10M	7.28M	8.08M	8.25M	8.71M	7.90M	4.19M	3.42M	3.87M	3.63M	3.48M	-24.93M			1.74M	-16.12M
Net Income towards Common Stockholders (Quarter)		-2.77M	-2.97M	-5.04M	-5.10M	7.28M	8.08M	8.25M	8.71M	7.90M	4.19M	3.42M	3.87M	3.63M	3.48M	-24.93M			1.74M	-16.12M
Additional items
EPS (Basic) (Quarter)	0.01	0.01	0.01	0.02	0.02	0.03	0.04	0.04	0.04	0.04		0.01	0.01	0.01	0.01	0.01			0.00	0.00
EPS (Weighted Average and Diluted) (Quarter)		0.01	0.01	0.02	0.02	0.03	0.04	0.04	0.04	0.04		0.01		0.01		-0.07				-0.03
Shares Outstanding (Weighted Average) (Quarter)	156.75M	186.84M	227.96M	207.47M	228.09M	228.17M	228.77M	227.59M	221.00M	221.67M		235.00M	284.15M	285.11M	350.64M	359.05M		459.83M	494.34M	510.23M
Shares Outstanding (Diluted Average) (Quarter)		216.27M	227.96M	207.47M	228.09M	228.17M	228.77M	227.59M	221.00M	221.67M		235.00M		285.11M		359.05M		459.83M		510.23M
EBITDA (Quarter)		-2.77M	-2.97M	-5.04M	-5.10M	7.21M	7.84M	7.88M	9.05M	8.20M	3.90M	2.99M	4.05M	3.77M	3.71M	-25.18M			1.84M	-16.22M
Interest Expenses (Quarter)						0.48M	-0.24M	-0.38M	0.32M	0.26M	-0.23M	-0.43M	0.18M	0.14M	0.23M	-0.25M	0.16M	0.20M	0.10M	-0.10M
Tax Rate (Quarter)						-8.08%		0.12%	0.24%	0.43%	-1.33%

Research Tools

Chemomab Therapeutics Income Statement (2017-2025) | CMMB

Create an account

Sign In

Reset Password